Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

RSS icon

New radiotracer IDs numerous cancers likely to respond to targeted therapy

The radiotracer, 68Ga-PentixaFor, can be used for detecting C-X-C motif chemokine receptor 4 (CXCR4), which plays a significant role in cancer progression.

Thumbnail

Cognitive decline not far behind amyloid and tau PET-positive scans, even for the asymptomatic

Common markers of Alzheimer's disease visualized on PET scans of asymptomatic patients might foreshadow the onset of symptoms in the years following their initial discovery.

Thumbnail

How a newly secured 3D printing patent could stabilize radioisotope production

Recently, a patent for 3D printed uranium targets was secured by the National Center for Nuclear Research (NCBJ) in Swierk, Poland, and it could increase the production of Molybdenum-99 (Mo-99) globally. 

NorthStar radiopharmaceutical development facility.

NorthStar breaks ground on new facility, will offer radiopharmaceutical development services to other companies

The 36,000 square foot unit will be located in Beloit, Wis., alongside NorthStar’s production facilities. It is expected to be open for business starting in 2024.

Thumbnail

Isotope shortage update: NMEU names potential restart date for downed reactor

On November 4, Nuclear Medicine Europe indicated inspections at the downed BR2 reactor had been finalized.

Thumbnail

Another isotope shortage looms as mechanical failure delays production

A new report suggests there may soon be a shortage of molybdenum-99 (Mo-99)/technetium-99m (Tc-99m). What does that mean for patient care in the months ahead? 

Barry L. Zaret, MD

Veteran cardiologist, viewed by many as the founder of nuclear cardiology, dies at 82

Barry L. Zaret, MD, was an influential cardiologist, accomplished poet and veteran of the United States Air Force. 

Thumbnail

PET/CT findings predict post-treatment, radiation-induced hypothyroidism

Radiation-induced hypothyroidism is common yet underdiagnosed, potentially owing to a lack of follow-up consensus in patients treated with radiation therapy for head and neck cancers.

Displaying 81 - 88 of 1400
Design by Adaptive Theme